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Abstract
Background.—Approximately 90% of genital warts are caused by human papillomavirus (HPV) 
types 6 and 11. In the United States, HPV vaccination has been recommended for girls and women 
aged ≤26 years, and since 2011, for boys and men aged ≤21 years and for gay, bisexual, and other 
men who have sex with men (MSM) aged ≤26 years.
Methods.—Data were obtained from 27 clinics participating in the STD Surveillance Network. 
Trends in the annual prevalence of anogenital warts (AGW) from 2010–2016 were described by 
sex and by the sex of sex partners.
Results.—During 2010–2016, significant declines in the prevalence of AGW were observed in 
women aged <40 years, men who have sex with women only (MSW) aged <40 years, and MSM of 
all age categories. An inflection in trend in 2012 was noted for MSW aged 20–24 or 25–29 years 
and for MSM aged 20–24 years.
Conclusions.—The observed declines in the prevalence of AGW suggest that HPV morbidity is 
declining among populations attending STD clinics, including MSW, MSM, and women. Declines 
in younger age groups are consistent with what would be expected following the implementation 
of HPV vaccination. However, declines were also observed in older age groups and are not likely 
to be the result of vaccination.
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Human papillomavirus (HPV) has been identified as the most common agent of sexually 
transmitted infections in the United States [1]. Many HPV infections appear to be transient 
and may not result in clinically significant outcomes [2–5]; however, persistent infections 
can cause adverse sequelae [4, 6]. HPV type 6 (HPV-6) and HPV-11 are associated with 
approximately 90% of genital warts (also referred to as anogenital warts [AGW]); HPV-16 
and −18 are associated with approximately 70% of cervical and other genital cancers [2, 7, 
8]. The quadrivalent HPV vaccine targets HPV-6, −11, −16, and −18 [2] and was licensed in 
the United States in mid-2006 for female individuals [9] and in late 2009 for male 
individuals [10]. Although a bivalent vaccine was also licensed for female individuals [11], 
almost all HPV vaccine administered in the United States through 2014 was quadrivalent 
[12]. A 9-valent vaccine, which protects against the quadrivalent types and 5 additional 
oncogenic HPV types (HPV-31, −33, −45, −52, and −58), was licensed in late 2014 for male 
and female individuals [13]. All HPV vaccines have been recommended by the Advisory 
Committee on Immunization Practices (ACIP) for routine use in US girls aged 11–12 years, 
with catch-up vaccination through age 26 years [9, 13]. Since October 2011, the ACIP has 
recommended that boys aged 11–12 years be vaccinated with either quadrivalent or 9-valent 
vaccine, with catch-up vaccination through age 21 years. The ACIP recommends catch-up 
vaccination through age 26 years for gay, bisexual, and other men who have sex with men 
(MSM) [14]. In the United States, HPV vaccine uptake (ie, coverage) has increased over 
time: in a 2016 national survey of adolescents aged 13–17 years, 65% of girls and 56% of 
boys had received ≥1 dose of HPV vaccine, compared with 49% and 1%, respectively, in 
2010 [15, 16]. In 2014, 17% of MSM included in a National HIV Behavioral Surveillance 
survey self-reported receiving ≥1 dose of HPV vaccine [17], although these data have not 
since been updated.
Monitoring the impact of HPV vaccination in the United States remains difficult as HPV 
infections can result in multiple clinical sequelae with variable and often extended times to 
manifestation [3, 18, 19]. Furthermore, few US data sources include person-level 
information on both HPV vaccination and HPV infection or clinical sequelae of infection. 
Because AGW can manifest within weeks to months of infection with HPV-6 and/or −11 
[3], the impact of vaccination on sequelae of HPV infection can most immediately be 
monitored through AGW surveillance [20]. Studies in the United States, Australia, and 
Europe have used AGW prevalence to document HPV morbidity trends [21–26]. In lieu of 
notifiable disease reports of AGW cases, US AGW morbidity studies have relied on 
healthcare claims data to identify trends in diagnoses [21–23]. However, the largest of these 
studies did not include populations that seek health care outside of commercial or employer-
covered plans [21, 22], which may be at increased risk of STIs [23], and none assessed 
AGW morbidity by sex of sex partner. No US study has reported trends in AGW diagnoses 
in MSM since the ACIP updated its vaccination recommendations in late 2011 to include 
male individuals. A 2010–2011 sexually transmitted disease (STD) clinic–based study 
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reported the prevalence of AGW to be 7.5% among men who have sex with women only 
(MSW), 7.5% among MSM, and 2.4% among women [20]. Our analysis uses the same STD 
clinic–based infrastructure to provide insight into the burden of AGW in key demographic 
groups. Specifically, our objectives were to describe age-specific trends in the annual 
prevalence of AGW among patients attending select US STD clinics from 2010–2016 
overall and by sex of male patients’ sex partners.
METHODS
Data were obtained from STD clinics participating in the Centers for Disease Control and 
Prevention’s STD Surveillance Network (SSuN) from January 2010 to December 2016 [27]. 
Data from 27 STD clinics in the following jurisdictions were included: Baltimore (2 clinics), 
Los Angeles (12), New York City (9, 2010–2014; 8, 2015–2016), Philadelphia (2), San 
Francisco (1), and Seattle (1). All jurisdictions submitted data through the entire study 
period. Analyses were restricted to visit types in which a patient was seen by a healthcare 
provider (ie, clinician visits); express/follow-up visits were excluded. Within each calendar 
year, patient visits were deduplicated so that unique patients per year were the unit of 
analysis. Demographic, behavioral, and clinical information was abstracted from electronic 
medical records and collated across patient visits per year. Human immunodeficiency virus 
(HIV) status was assessed through laboratory testing or, if known to be living with 
diagnosed HIV, self-reporting. Sexual behavior was determined by patient self-report of 
male and/or female sex partners or by self-reported sexual orientation (eg, “gay” or 
“straight”). Men who identified as gay or bisexual or who reported having sex with a man at 
any of their visits for the year were classified as MSM. Men who identified as heterosexual 
only or reported only female sex partners at any time during the year were classified as 
MSW. Sex partnerships among women were not considered, as only 2% of women reported 
having sex with women only. Six percent of the male population for whom the sex of sex 
partners was unknown were excluded from the trend analyses, as were patients who reported 
being transgender (<1%).
Case Definition
An AGW case was defined as a patient with an AGW diagnosis, identified from electronic 
medical records, at ≥1 visit within a calendar year. Diagnoses were based on clinical 
evaluation and physical examination findings.
Statistical Analysis
Analyses were conducted using SAS, version 9.4 (SAS Institute, Cary, NC). The annual 
prevalence of AGW was estimated using a random-effects meta-analysis model to account 
for the substantial diversity in patient demographic characteristics and AGW prevalence 
across the SSuN jurisdictions. The random-effects model incorporates heterogeneity across 
the jurisdictions by allowing each jurisdiction to have a different true prevalence, which is 
assumed to have been sampled from a population of true prevalences. To calculate the 
overall annual AGW prevalence, we first calculated the total number of unique persons with 
an AGW diagnosis in a year in a jurisdiction, divided by the total number of unique persons 
with ≥1 clinician visit in that jurisdiction that year. Then, using the year and jurisdiction-
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specific estimates, we estimated the overall annual AGW prevalence, using an inverse-
variance weighted random effects model (the SAS macro containing programming code for 
model is available on request). To examine temporal trends, the percentage change in 
prevalence (adjusted for jurisdiction) over the study period was calculated as the difference 
between the prevalence of AGW in 2010 as compared to that in 2016, divided by the 
prevalence in 2010. Joinpoint software, version 4.4.0 (National Cancer Institute, Bethesda, 
MD), which fits trend data to identify the log-linear model with the fewest number of 
inflection points, was used to identify significant trends in adjusted annual AGW 
prevalences [28]. The annual percentage change (APC) in adjusted AGW prevalence was 
estimated by Joinpoint, using the log-linear slope of trend segments between inflection 
points [28]. All analyses were also conducted by age group, sex, and sex of the male 
patient’s sex partner; patients missing these stratifying variables were excluded from trend 
analyses.
RESULTS
Approximately 650 000 patients had at least one clinician visit in a participating SSuN STD 
clinic from 1 January 2010 through 31 December 2016. The number of patients attending 
the clinics declined over the study period, from 108 524 patients in 2010 to 74 690 patients 
in 2016 (Table 1). The median age was 26 years for women (mean age [±SD], 28.9 ± 10.4 
years), 29 years for MSW (mean age [±SD], 32.5 ± 11.3 years), and 31 years for MSM 
(mean age [±SD], 33.6 ± 10.7 years). The mean age (±SD) of all patients increased slightly 
over time, from 30.5 ± 11.0 years in 2010 to 33.0 ± 11.5 years in 2016. Approximately half 
of the population was non-Hispanic black; 21% of patients was Hispanic, and 20% was non-
Hispanic white. Sixty-three percent of the population was male, and 29% of male patients 
were identified as MSM. The proportion of men who were MSM increased from 12.9% in 
2010 to 23.4% in 2016. Approximately 4% of the population was known to be living with 
diagnosed HIV infection, although the proportion increased from 3.2% in 2010 to 5.2% in 
2016; among MSM only, the proportion ranged from 18.0% to 19.2% but did not 
significantly increase over the study period. The proportion of patients known to be living 
with diagnosed HIV infection was higher among MSM (18.7%) than among MSW (0.9%) 
or women (0.7%). During 2015–2016, compared with the preceding years, there were 
increases in the proportion of patients for whom the following characteristics were 
unknown: age (from 0% to approximately 5%), sex (from <1% to approximately 5%), race/
ethnicity (from approximately 3% to approximately 8%), and sex of sex partners (from 
approximately 2% to approximately 8%).
Substantial diversity in patient demographic characteristics and AGW prevalence existed 
across jurisdictions (data not shown). For example, across the study period, 31% of the 
patient population in Los Angeles was Hispanic, compared with 4% in San Francisco. 
Thirty-nine percent of the San Francisco patient population was MSM, compared with 5% in 
Baltimore. Eight percent of the San Francisco patient population was known to be living 
with diagnosed HIV infection, compared with 2% in Los Angeles. The jurisdiction with the 
highest prevalence of AGW during the study period was Seattle, at 5.5%, and the lowest was 
Baltimore, at 2.8%.
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The overall prevalence of AGW, adjusted for jurisdiction, was highest in MSW (6.3%; 95% 
CI, 5.3%–7.4%), followed by MSM (4.6%; 95% CI, 4.2%–5.1%), and women (1.8%; 95% 
CI, 1.5%–2.1%). The overall unadjusted prevalence of AGW was 5.9% in MSW, 4.6% in 
MSM, and 1.6% in women.
Trends in the Prevalence of AGW
The overall prevalence of AGW among women, adjusted for jurisdiction, decreased 
significantly, from 2.3% in 2010 to 0.9% in 2016 (APC, −13.1%; 95% CI, −16.4% to 
−9.7%) (Figure 1). Among women aged ≤39 years, the annual prevalence decreased 
significantly during 2010–2016 (Table 2). The AGW prevalence among women aged <20 
years decreased from 1.8% in 2010 to 0.5% in 2016 (APC, −17.2%; 95% CI, −21.3% to 
−12.8%; Figure 2). Among 20–24 year olds, the prevalence decreased from 2.8% in 2010 to 
1.0% in 2016 (APC, −16.4%; 95% CI, −20.1% to −12.5%). Among 25–29 year olds, the 
prevalence was 2.3% in 2010, declining to 0.8% in 2016 (APC,–13.8%; 95% CI, −17.2% to 
−10.3%), while among 30–39 year olds, the prevalence decreased from 2.1% to 0.8% (APC, 
−11.7%; 95% CI, −18.7% to −4.2%). Women aged >39 years experienced declines in AGW 
prevalences across the study period, although the decreases were not statistically significant.
The overall jurisdiction-adjusted prevalence of AGW among all MSW decreased 
significantly during 2010–2016, from 7.3% to 4.4% (APC, −8.1%; 95% CI, −10.4% to 
−5.6%). MSW aged ≤39 years experienced statistically significant declines in AGW 
prevalence during the study period. Among MSW aged <20 years, the prevalence decreased 
significantly, from 2.7% in 2010 to 0.6% in 2016 (APC, −14.5%; 95% CI, −25.4% to 
−1.9%). Between 2010 and 2012, the prevalence among MSW aged 20–24 years was stable 
but decreased significantly during 2012–2016, from 6.3% to 2.4% (APC, −20.4; 95% CI, 
−27.3% to −12.9%) Similarly, between 2010 and 2012, the prevalence was stable among 
MSW aged 25–29 years but decreased significantly from 2012 to 2016, from 8.4% to 4.6% 
(APC, −14.8%, 95% CI, −16.6% to −13.0%). The prevalence of AGW significantly 
decreased among MSW aged 30–39 years (APC, −5.0%, 95% CI, −7.1% to −2.8%) but did 
not significantly decrease among MSW aged >39 years (APC, −1.4%, 95% CI, −3.8%–
1.2%).
The prevalence of AGW among all MSM decreased significantly during 2010–2016, from 
6.2% to 2.9% (APC, −11.3%;95% CI, −13.1% to −9.4%). Decreases were significant in all 
age categories of MSM. Among MSM aged <20 years, the prevalence decreased from 8.0% 
in 2010 to 2.3% in 2016 (APC, −18.8%; 95% CI, −30.0% to −5.9%). Between 2010 and 
2012, the prevalence among MSM aged 20–24 years did not significantly change but 
decreased significantly from 2012 to 2016, from 8.3% to 3.1% (APC, −18.1; 95% CI, 
−32.0% to −1.3%). Additionally, from 2010 to 2016, the prevalence of AGW decreased 
significantly among MSM aged 25–29 years, from 7.5% to 3.2% (APC, −13.2%; 95% CI, 
−16.7% to −9.6%); among MSM aged 30–39 years, from 5.6% to 3.1% (APC, −9.5%; 95% 
CI, −12.6% to −6.3%); and among MSM aged >39 years, from 3.6% to 2.2% (APC, −7.7%; 
95% CI, −9.3% to −6.1%). Similar trends in the prevalence of AGW among women, MSW, 
and MSM were observed in individual jurisdictions.
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DISCUSSION
Using STD clinic data, we report the first temporal trends in the prevalence of AGW in the 
United States, by patient sex and the sex of male patients’ sex partners. We document 
declines in the AGW prevalence across all populations, with statistically significant declines 
among women aged ≤39 years, among MSW aged ≤39 years, and among MSM of all ages. 
These declines suggest that HPV morbidity is decreasing among patients attending SSuN 
STD clinics. The drivers of these decreases are unclear. It is likely that some of the observed 
decreases may be related to expanded HPV vaccination coverage, but it is also possible that 
observed declines may have been influenced by changes in the patient population accessing 
care in STD clinics and/or by variations in AGW testing and diagnoses by STD clinic 
providers.
HPV vaccination may explain some of the observed declines, particularly among 
populations for which HPV vaccination is recommended. For example, the observed steady 
declines in women aged <30 years are consistent with what would be expected following the 
initiation of routine HPV vaccination; all women in this group would have been age eligible 
for HPV vaccination before or during the study period. Additionally, there were significant 
declines in the AGW prevalence in both MSM and MSW aged <40 years. The ACIP has 
recommended catch-up HPV vaccination for men through age 21 years since 2011; all male 
individuals aged <20 years and most aged 20–24 years would have been age eligible for 
vaccination during part of the study period. The prevalence among MSW aged 20–29 years 
remained stable from 2010 to 2012 but decreased significantly from 2012 to 2016. This 
inflection in trend in 2012 coincides with the ACIP’s October 2011 recommendation to 
vaccinate men. Declines in the AGW prevalence among MSW may also be partially 
attributed to herd protection from female vaccination, as female cervicovaginal HPV 
prevalence and female AGW morbidity in younger age groups has continuously decreased 
since the ACIP recommended female vaccination in 2006 [21, 22, 29]. Since 2011, the ACIP 
has recommended catch-up HPV vaccination for MSM through age 26 years. Similar to 
MSW, an inflection in trend was observed in 2012 for MSM aged 20–24 years. However, 
unlike MSW or women, statistically significant declines in AGW diagnoses among MSM 
>39 years were observed. Although older MSM are less likely to be HPV naive and may not 
directly benefit from vaccination, observed decreases may be partially due to herd protection 
via sex partnerships with younger men, which may be more common among MSM as 
compared to MSW or women [30].
The observed declines in populations that were not age eligible argue against vaccination 
being the primary catalyst for our observed findings and may reflect changes in the patient 
population attending these clinics. During the study period, the overall number of patients 
attending SSuN STD clinics decreased by approximately 30%, which would affect the 
absolute number of AGW diagnoses over time. We accounted for the decreasing population 
size by estimating AGW morbidity as a proportion of all patients; however, we were unable 
to account for possible changes in the attributes of patients attending STD clinics. If, over 
time, more persons with AGW chose to seek care in non-STD clinics, including private 
facilities and community health centers, we would observe a decline in clinic prevalence 
independent of changes in population prevalence. Changes in where people seek care for 
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AGW may reflect changes in the healthcare system (eg, increasing insurance coverage may 
lead to more use of private facilities). Additionally, fiscal cuts to STD clinics may have 
resulted in changes in clinic operating hours and staff shortages, leading to a prioritization of 
patients with acute STIs, such as syphilis or symptomatic urethritis. Finally, because we 
estimated AGW morbidity as a proportion to account for changing clinic population size, the 
observed prevalence is affected by the incidence of other STIs in the general population. For 
example, if the syphilis incidence increases, more patients with syphilis would access care, 
and the observed clinic prevalence of AGW would decrease independent of the population 
prevalence.
Another possible explanation for the observed declines may be related to changes in clinical 
practice. The clinical criteria for identifying or diagnosing AGW did not change throughout 
the study period. However, there is no laboratory test for AGW, and HPV testing is not 
routine in STD clinics, so AGW are generally diagnosed by physical examination. It is 
possible that the proportion of AGW cases that were present but not detected or that were 
misdiagnosed increased over time owing to a decrease in physical examinations. If clinics 
increased self-collection of specimens for STI testing (eg, self-collected vaginal swabs for 
chlamydia testing), fewer patients may have had direct visual inspection of their genitals, 
resulting in fewer diagnoses of AGW independent of changes in population prevalence. This 
may be especially relevant for observed trends in female patients, as male genitalia may be 
easier to inspect visually as compared to female genitalia, which requires a pelvic 
examination. Because documentation of whether a comprehensive physical examination was 
performed was not captured consistently during the study period, we restricted our analysis 
to visits where a patient was seen by a provider, to minimize this possible bias.
Our results complement the few studies that have examined US trends in HPV and AGW 
prevalence. A 2006–2014 study assessed AGW trends among privately insured male and 
female individuals and found significant declines among girls and women aged 15–19 years 
(2008–2014), 20–24 years (2009–2014), and 25–29 years (2009–2014) and among men aged 
20–24 years (2009–2014) [22]. We found additional significant declines in older groups, 
including women aged 30–39 years, MSW aged 25–39 years, and MSM aged >25 years. 
However, our study was conducted through 2016 and likely included publicly insured and 
uninsured patients. To better understand the burden of disease among larger segments of the 
population, future studies should include both uninsured and insured (publicly or privately) 
individuals in a variety of healthcare settings. Additionally, our observed declines in AGW 
prevalence among women compliment studies that used National Health and Nutritional 
Examination Survey data to document declines in the prevalence of quadrivalent HPV 
vaccine types from cervicovaginal specimens; one study documented declines in girls and 
women aged 14–24 years between 2003 and 2006 (the prevaccine era) and 2009–2012 (the 
postvaccine era) [31]. Our study found additional significant declines in women aged 25–39 
years; however, comparison between these studies is difficult because our study captured 
only AGW, not HPV, prevalence and was conducted through 2016.
This study has several limitations. This study used data from STD clinics located in urban 
centers, limiting geographical representativeness. However, substantial diversity in patient 
demographic characteristics and the prevalence of AGW existed across jurisdictions. 
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Interjurisdictional variations were adjusted for and therefore should not affect the reported 
trends in AGW prevalence. Second, linking patients across the full study period was not 
possible, so our study design would not preclude the inclusion of AGW cases in the same 
patients across multiple years. Also, since demographic and behavioral data were abstracted 
from medical records in each calendar year and because matching visits by unique patients 
was possible within years, cases with multiple visits in a year had more opportunities for 
more complete ascertainment of behavioral and/or demographic patient information (eg, the 
ability to be identified as MSM or MSW) when compared to patients with only 1 visit. 
However, the overall proportion of patients with missing information was low (ie, <5%) 
throughout the study period; therefore, this should have a minimal effect on trends. Last, our 
study lacked data on patients’ HPV vaccination status. This would be especially useful for 
elucidating the link between HPV vaccination status and AGW prevalence among groups 
that were age eligible for vaccination but have had historically low coverage rates. 
Vaccination information would also aid in understanding whether STD clinic patients are 
more or less likely to be vaccinated for HPV than the general population. Many STD clinics 
do not routinely vaccinate for HPV [32], although individuals may be vaccinated at other 
venues.
Despite these limitations, these data represent the first US evaluation of AGW trends among 
patients attending STD clinics. While patients attending STD clinics are not likely to 
represent all persons with AGW, they remain an important population with a higher burden 
of STIs [33]. The impact of STD prevention interventions may be more easily detected 
among such groups with higher STI morbidity. In conclusion, given the prophylactic 
efficacy and high population effectiveness of the HPV vaccine [34, 35] and that the age 
groups that were age eligible for the HPV vaccine experienced the sharpest decreases in 
AGW prevalence, it is likely that the observed decline in the proportion of patients attending 
STD clinics with AGW is partially the result of US implementation of HPV vaccination. 
However, our study is ecologic by design, and declines were observed in age groups that are 
not targeted for vaccination and are thus less likely to be affected, suggesting that other 
factors may be impacting observed trends. Continued surveillance for AGW can help 
monitor the impact of vaccination and other prevention and control activities.
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Figure 1. 
Annual anogenital wart prevalence among patients attending US Sexually Transmitted 
Disease Surveillance Network clinics, by patient type (which takes into account the sex of 
male patients’ sex partners), 2010–2016. Error bars denote 95% confidence intervals. 
aIncludes men who have sex with men and women.
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Figure 2. 
Annual anogenital wart prevalence among patients attending US Sexually Transmitted 
Disease Surveillance Network clinics, by age category and patient type (which takes into 
account the sex of male patients’ sex partners), 2010–2016. Error bars denote 95% 
confidence intervals. aIncludes men who have sex with men and women.
Mann et al. Page 12
J Infect Dis. Author manuscript; available in PMC 2020 April 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Mann et al. Page 13
Ta
bl
e 
1.
D
em
og
ra
ph
ic
 a
nd
 C
lin
ic
al
 C
ha
ra
ct
er
ist
ic
s o
f P
at
ie
nt
s A
tte
nd
in
g 
Se
x
u
al
ly
 T
ra
n
sm
itt
ed
 D
ise
as
e 
(S
TD
) C
lin
ics
 Pa
rt
ic
ip
at
in
g 
in
 th
e 
U
S 
ST
D
 S
ur
ve
ill
an
ce
 
N
et
w
o
rk
, 2
01
0–
20
16
C
ha
ra
ct
er
ist
ic
20
10
 (n
 = 
10
8 
52
4)
20
11
 (n
 = 
10
5 
98
4)
20
12
 (n
 = 
10
0 
12
3)
20
13
 (n
 = 
95
 
54
8)
20
14
 (n
 = 
87
 
65
4)
20
15
 (n
 = 
81
 
32
4)
20
16
 (n
 = 
74
 
69
0)
O
ve
ra
ll 
(n
 = 
65
3 
84
7)
Ju
ris
di
ct
io
n
 
B
al
tim
or
e
13
 2
80
 (1
2.2
)
12
 7
69
 (1
2.0
)
11
 5
54
 (1
1.5
)
11
 0
88
 (1
1.6
)
92
41
 (1
0.5
)
60
58
 (7
.4)
53
19
 (7
.1)
69
 3
09
 (1
0.6
)
 
Lo
s A
ng
el
es
23
 8
26
 (2
2.0
)
22
 0
08
 (2
0.8
)
19
 7
97
 (1
9.8
)
18
 4
08
 (1
9.3
)
16
 7
71
 (1
9.1
)
16
 7
11
 (2
0.5
)
15
 2
11
 (2
0.4
)
13
2 
73
2 
(20
.3)
 
N
ew
 Y
o
rk
 C
ity
43
 5
38
 (4
0.1
)
43
 5
04
 (4
1.0
)
41
 9
72
 (4
1.9
)
39
 3
30
 (4
1.2
)
35
 7
01
 (4
0.7
)
31
 4
49
 (3
8.7
)
28
 5
65
 (3
8.2
)
26
4 
05
9 
(40
.4)
 
Ph
ila
de
lp
hi
a
10
 0
37
 (9
.2)
98
95
 (9
.3)
95
24
 (9
.5)
99
16
 (1
0.4
)
10
 0
61
 (1
1.5
)
99
63
 (1
2.3
)
96
77
 (1
3.0
)
69
 0
73
 (1
0.6
)
 
Sa
n 
Fr
an
ci
sc
o
10
 3
86
 (9
.6)
10
 7
81
 (1
0.2
)
10
 1
17
 (1
0.1
)
99
23
 (1
0.4
)
97
30
 (1
1.1
)
10
 5
74
 (1
3)
97
83
 (1
3.1
)
71
 2
94
 (1
0.9
)
 
W
as
hi
ng
to
n
74
57
 (6
.9)
70
27
 (6
.6)
71
59
 (7
.2)
68
83
 (7
.2)
61
50
 (7
.0)
65
69
 (8
.1)
61
35
 (8
.2)
47
 3
80
 (7
.2)
A
ge
, y
 
≤1
9
11
 9
31
 (1
1.0
)
10
 4
43
 (9
.9)
86
19
 (8
.6)
70
59
 (7
.4)
57
65
 (6
.6)
42
20
 (5
.2)
38
28
 (5
.1)
51
 8
69
 (7
.9)
 
20
–2
4
27
 9
99
 (2
5.8
)
26
 8
51
 (2
5.3
)
24
 3
85
 (2
4.4
)
22
 2
96
 (2
3.3
)
19
 6
92
 (2
2.5
)
15
 9
06
 (1
9.6
)
13
 3
92
 (1
7.9
)
15
0 
52
1 
(23
.0)
 
25
–2
9
22
 6
41
 (2
0.9
)
23
 1
15
 (2
1.8
)
22
,1
86
 (2
2.2
)
21
 7
55
 (2
2.8
)
20
 8
21
 (2
3.8
)
18
 8
34
 (2
3.2
)
17
 7
58
 (2
3.8
)
14
7 
11
0 
(22
.5)
 
30
–3
9
23
 8
52
 (2
2.0
)
23
 8
06
 (2
2.5
)
23
,3
61
 (2
3.3
)
23
 2
64
 (2
4.3
)
21
 8
03
 (2
4.9
)
20
 0
70
 (2
4.7
)
19
 4
00
 (2
6.0
)
15
5 
55
6 
(23
.8)
 
≥4
0
22
 1
00
 (2
0.4
)
21
 7
69
 (2
0.5
)
21
,5
71
 (2
1.5
)
21
 1
74
 (2
2.2
)
19
 5
71
 (2
2.3
)
17
 8
50
 (2
1.9
)
17
 4
22
 (2
3.3
)
14
1 
45
7 
(21
.6)
 
U
nk
no
w
n
1 
(0.
0)
0 
(0.
0)
1 
(0.
0)
0 
(0.
0)
2 
(0.
0)
44
44
 (5
.5)
28
90
 (3
.9)
73
34
 (1
.1)
Se
x
 
Fe
m
al
e
42
 2
89
 (3
9.0
)
40
 9
25
 (3
8.6
)
37
 1
42
 (3
71
)
33
 8
35
 (3
5.4
)
30
 1
56
 (3
4.4
)
25
 9
32
 (3
1.9
)
21
 4
83
 (2
8.8
)
23
1,
76
2 
(35
.4)
 
M
al
e
66
 0
76
 (6
0.9
)
64
 9
01
 (6
1.2
)
62
 7
65
 (6
2.7
)
61
 4
91
 (6
4.4
)
57
 2
52
 (6
5.3
)
53
 9
25
 (6
6.3
)
46
 9
10
 (6
2.8
)
41
3,
32
0 
(63
.2)
 
Tr
an
sg
en
de
r
14
6 
(0.
1)
14
7 
(0.
1)
16
8 
(0.
2)
18
4 
(0.
2)
18
7 
(0.
2)
21
2 
(0.
3)
27
5 
(0.
4)
13
19
 (0
.2)
 
U
nk
no
w
n
13
 (0
.0)
11
 (0
.0)
48
 (0
.0)
38
 (0
.0)
59
 (0
.1)
12
55
 (1
.5)
60
22
 (8
.1)
74
46
 (1
.1)
R
ac
e/
et
hn
ic
ity
 
N
on
-H
isp
an
ic
 b
la
ck
56
 5
54
 (5
2.1
)
53
 8
40
 (5
0.8
)
50
 1
28
 (5
0.1
)
47
 3
50
 (4
9.6
)
42
 4
73
 (4
8.5
)
36
 1
62
 (4
4.5
)
32
 8
62
 (4
4.0
)
31
9 
36
9 
(48
.8)
 
H
isp
an
ic
22
 8
70
 (2
1.1
)
22
 1
78
 (2
0.9
)
21
 0
11
 (2
1.0
)
19
 7
88
 (2
0.7
)
18
 0
99
 (2
0.6
)
15
 6
00
 (1
9.2
)
15
 4
69
 (2
0.7
)
13
5 
01
5 
(20
.6)
 
N
on
-H
isp
an
ic
 w
hi
te
20
 0
24
 (1
8.5
)
19
 7
11
 (1
8.6
)
19
 4
20
 (1
9.4
)
19
 3
25
 (2
0.2
)
18
 0
44
 (2
0.6
)
16
 8
16
 (2
0.7
)
15
 4
22
 (2
0.6
)
12
8 
76
2 
(19
.7)
 
O
th
er
64
59
 (6
.0)
65
43
 (6
.2)
65
09
 (6
.5)
63
08
 (6
.6)
60
75
 (6
.9)
57
58
 (7
.1)
56
00
 (7
.5)
43
 2
52
 (6
.6)
 
U
nk
no
w
n
26
17
 (2
.4)
37
12
 (3
.5)
30
55
 (3
.1)
27
77
 (2
.9)
29
63
 (3
.4)
69
88
 (8
.6)
53
37
 (7
.1)
27
 4
49
 (4
.2)
Pa
tie
nt
 ty
pe
a
 
W
o
m
en
42
 2
89
 (3
9.0
)
40
 9
25
 (3
8.6
)
37
 1
44
 (3
7.1
)
33
 8
35
 (3
5.4
)
30
 1
56
 (3
4.4
)
25
 9
33
 (3
1.9
)
21
 4
84
 (2
8.8
)
23
1 
76
6 
(35
.4)
J Infect Dis. Author manuscript; available in PMC 2020 April 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Mann et al. Page 14
C
ha
ra
ct
er
ist
ic
20
10
 (n
 = 
10
8 
52
4)
20
11
 (n
 = 
10
5 
98
4)
20
12
 (n
 = 
10
0 
12
3)
20
13
 (n
 = 
95
 
54
8)
20
14
 (n
 = 
87
 
65
4)
20
15
 (n
 = 
81
 
32
4)
20
16
 (n
 = 
74
 
69
0)
O
ve
ra
ll 
(n
 = 
65
3 
84
7)
 
M
SW
49
 0
97
 (4
5.2
)
47
 1
46
 (4
4.5
)
44
 9
34
 (4
4.9
)
41
 9
90
 (4
3.9
)
38
 6
04
 (4
4.0
)
33
 3
33
 (4
1.0
)
26
 9
83
 (3
6.1
)
28
2 
08
7 
(43
.1)
 
M
SM
14
 0
49
 (1
2.9
)
15
 2
57
 (1
4.4
)
15
 9
28
 (1
5.9
)
17
 2
58
 (1
8.1
)
16
 7
62
 (1
9.1
)
17
 6
66
 (2
1.7
)
17
 4
89
 (2
3.4
)
11
4 
40
9 
(17
5)
 
Tr
an
sg
en
de
r
15
8 
(0.
1)
15
6 
(0.
1)
18
0 
(0.
2)
19
6 
(0.
2)
20
3 
(0.
2)
26
0 
(0.
3)
30
0 
(0.
4)
14
53
 (0
.2)
 
U
nk
no
w
n
 s
ex
 o
f s
ex
 
pa
rtn
er
s
29
31
 (2
.7)
25
00
 (2
.4)
19
37
 (1
.9)
22
69
 (2
.4)
19
29
 (2
.2)
41
32
 (5
.1)
84
34
 (1
1.3
)
24
 1
32
 (3
.7)
H
IV
 in
fe
ct
io
n 
sta
tu
s
 
K
no
w
n
 to
 b
e 
liv
in
g 
w
ith
 
di
ag
no
se
d 
H
IV
 in
fe
ct
io
n
34
66
 (3
.2)
35
52
 (3
.4)
38
00
 (3
.8)
40
19
 (4
.2)
39
75
 (4
.5)
39
75
 (4
.9)
38
48
 (5
.2)
26
 6
11
 (4
.1)
 
N
ot
 k
no
w
n
 to
 b
e 
liv
in
g 
w
ith
 d
ia
gn
os
ed
 H
IV
 in
fe
ct
io
n
10
5 
05
8 
(96
.8)
10
2 
43
2 
(96
.6)
96
 3
23
 (9
6.2
)
91
 5
29
 (9
5.8
)
83
 6
79
 (9
5.5
)
77
 3
73
 (9
5.1
)
70
 8
42
 (9
4.8
)
62
7 
23
6 
(95
.9)
D
at
a 
ar
e 
no
. (%
) o
f p
ati
en
ts
A
bb
re
v
ia
tio
ns
: H
IV
,
 
hu
m
an
 im
m
un
od
ef
ic
ie
nc
y 
vi
ru
s; 
M
SM
, m
en
 w
ho
 h
av
e 
se
x
 w
ith
 m
en
; M
SW
,
 
m
en
 w
ho
 h
av
e 
se
x
 w
ith
 w
o
m
en
 o
n
ly
.
a T
ak
es
 in
to
 a
cc
ou
nt
 th
e 
se
x
 o
f m
al
e 
pa
tie
nt
s’
 se
x
 p
ar
tn
er
s.
J Infect Dis. Author manuscript; available in PMC 2020 April 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Mann et al. Page 15
Table 2.
Trends in Prevalence of Anogenital Warts, by Patient Type and Age Category and Adjusted for Jurisdiction—
US Sexually Transmitted Disease Surveillance Network, 2010–2016
Variable Percentage Change in Prevalencea,b Annual Percentage Change in Prevalencea,c (95% CI)
Overall −47.1 −8.8 (−11.3 to −6.1)
Patient typed
 Women −62.2 −13.1 (−16.4 to −9.7)
 MSW −39.0 −8.1 (−10.4 to −5.6)
 MSM −53.4 −11.3 (−13.1 to −9.4)
Age category, y
 Among women
  ≤19 −71.1 −17.2 (−21.3 to −12.8)
  20–24 −64.3 −16.4 (−20.1 to −12.5)
  25–29 −64.0 −13.8 (−17.2 to −10.3)
  30–39 −60.4 −11.7 (−18.7 to −4.2)
  ≥40 −81.9 −9.9 (−12.3 to 3.8)
 Among MSW
  ≤19 −76.2 −14.5 (−25.4 to −1.9)
  20–24e −66.4 …
   2010–2012 … −4.6 (−32.4–34.5)
   2012–2016 … −20.4 (−27.3 to −12.9)
  25–29e −51.5 …
   2010–2012 … −4.3 (−14.0 to −6.5)
   2012–2016 … −14.8 (−16.6 to −13.0)
  30–39 −24.9 −5.0 (−7.1 to −2.8)
  ≥40 −7.1 −1.4 (−3.8–1.2)
 Among MSM
  ≤19 −70.7 −18.8 (−30.0 to −5.9)
  20–24e −61.8 …
   2010–2012 … −0.2 (−27.2–36.9)
   2012–2016 … −18.1 (−32.0 to −1.3)
  25–29 −57.3 −13.2 (−16.7 to −9.6)
  30–39 −43.9 −9.5 (−12.6 to −6.3)
  ≥40 −38.3 −7.7 (−9.3 to −6.1)
Abbreviations: CI, confidence interval; MSM, men who have sex with men; MSW, men who have sex with women only.
aCalculated for trend segments, defined as the period between inflection points.
b
Trend segments lasted from 2010 to 2016.
c
Trend segments lasted from 2010 to 2016, unless otherwise indicated.
d
Takes into account the sex of male patients’ sex partners.
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e
Trend segments were split into 2010–2012 and 2012–2016 because 2012 was an inflection year.
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